Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2000-Year of the Biotechs! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (463)	3/7/2000 6:38:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 1142

Torben, I think today's action has given investors a golden opportunity to pick up some shares of NABI and AQLA at a decent price level. The late afternoon sell-off I think was dictated by the DJIA debacle and shouldn't have touched either stock. When it comes to AQLA, I keep looking back to the investment that the Wisconsin Investment Board made in the company last year. Considering that the Un. of Wisconsin is behind the testing of the Quilvax product for mastitis, you would have to think that they "know" what potential the product has in being approved by the USDA. The phase III results should be finalized in the 2nd Q, and a marketing partnership should be near approval. IMO this will give the stock a nice bump UP. From a recent report from AQLA: The cash and investments balance was $7.0 million at December 31, 1999, a decrease of $8.1 million from December 31, 1998. In July of 1999, Aquila completed a $1.5 million private limited placement of newly issued common stock with the State of Wisconsin Investment Board. In February 2000, Aquila received $0.6 million in payments from two partners and proceeds of $0.6 million from sale of an investment. "During 1999, we initiated the final, pivotal product licensing studies of Quilvax-M(TM), scheduled to be completed by the second quarter of this year. We also granted a license to Neuralab Limited, a new subsidiary of Elan Corporation, plc to use our Stimulon(R) adjuvant in their Alzheimer's disease program," said Jim Warren, CFO of Aquila. Mr. Warren added that also during the year, Aquila received an SBIR Phase II grant to support development of its novel CD1 immune enhancement technology